Funding for this research was provided by:
KWF Kankerbestrijding (11089–2017/1)
Received: 3 March 2021
Accepted: 30 April 2021
First Online: 10 May 2021
: All animal experiments were supported by research grants from the University of Groningen, the University Medical Center Groningen, and the de Cock-Hadders Stichting.
: Not applicable.
: WdD was a member of the advisory board for GBM diagnostic testing for AbbVie. MdJ has an unrelated 8 investigator-initiated project contract with Advanced Accelerator Applications, a Novartis company. No potential conflicts of interest relevant to this article exist.